Tirzepatide

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has emerged as the predominant of heart failure (HF), particularly among aging populations and individuals with a high burden of comorbidities. Its underlying pathophysiological mecha…

BACKGROUND: Metabolic and bariatric surgery (MBS) is the most effective treatment for severe obesity, producing durable weight loss and improvement in obesity-related comorbidities. However, a subset of patients experience inadequate weight loss (non…

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual incretin therapies produce substantial weight loss and cardiometabolic improvement, yet treatment discontinuation is common and associated with adverse metabolic consequences.…

Glucagon-like peptide-1 (GLP-1)-based obesity pharmacotherapies have revolutionized obesity treatment. In this review, we discuss the discovery of GLP-1 and evaluate the efficacy of marketed and investigational GLP-1 receptor (GLP-1R) agonists (GLP-1…

The aggregation of the 42-residue form of the amyloid-β peptide (Aβ) is important in Alzheimer's disease (AD). Preclinical and clinical findings support that glucagon-like peptide-1 receptor agonists (GLP-1RAs) can protect against neuroinflammation a…

INTRODUCTION: Obesity is a global public health issue, with its effects a particular issue in Kuwait. Advances in pharmaceutical treatment (eg, glucagon-like peptide-1s) offer an effective solution, with the magnitude of weight lost something to cele…

Incretins have improved the management of obesity and its related complications, but maintaining these health benefits requires ongoing administration, which can be challenging. Orforglipron, a once-daily oral nonpeptide glucagon-like peptide-1 (GLP-…

OBJECTIVES: To investigate the clinical characteristics of weight loss drugs (WLDs) users in Norway. DESIGN: Nested population-based case-control study. SETTING: Nationwide healthcare registries with data on dispensed medications and healthcare diagn…

Two out of 5 US adults live with obesity, generating substantial clinical and economic burden. Recent glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide, demonstrate significant weight loss and cardiometaboli…

Over the last decade, significant progress has been made in cardiorenal protection for metabolic diseases such as type 2 diabetes (T2D) and obesity. With an expanding range of pharmacological options and continuously evolving guidelines, glucagon-lik…

Tirzepatide has been approved for the management of obesity, obstructive sleep apnea, and type 2 diabetes mellitus; while gastrointestinal side effects are commonly seen, ischemic colitis has been only rarely described. We present the case of a 32-ye…

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes in addition to other conditions such as obesity. As their use expands, understanding potential ocular safety signals is important, particularly in p…

BACKGROUND: Real-world data directly comparing the safety, tolerability, and effectiveness of semaglutide and tirzepatide in patients with obesity remain limited. This nationwide multicenter observational study compared short-term adverse events, tre…

BACKGROUND: Cardiovascular disease (CVD) and chronic kidney disease (CKD) frequently coexist, with obesity and type 2 diabetes (T2D) being major contributors to adverse outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and tirzepatide ha…

PURPOSE OF REVIEW: Overweight and obesity are increasingly common in people with type 1 diabetes mellitus (T1DM). This narrative review synthesizes current evidence on the epidemiology and mechanisms linking excess adiposity with T1DM, the obesity-as…

Background Cellulite is a highly prevalent condition associated with alterations in adipose tissue architecture, microcirculation, and connective tissue integrity. Emerging evidence suggests that cellulite may represent a manifestation of both local…